Skip to main content
Top
Published in: Inflammation 2/2022

01-04-2022 | SARS-CoV-2 | Original Article

Neutrophil Extracellular Trap Formation Potential Correlates with Lung Disease Severity in COVID-19 Patients

Authors: Nedha Kinnare, Jessica S Hook, Parth A Patel, Nancy L Monson, Jessica G Moreland

Published in: Inflammation | Issue 2/2022

Login to get access

Abstract

Severe lung inflammation is common in life-threatening coronavirus disease 2019 (COVID-19). This study tested the hypothesis that polymorphonuclear (PMN, neutrophil) phenotype early in the course of disease progression would predict peak lung disease severity in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is increasingly evident that PMN activation contributes to tissue injury resulting from extracellular reactive oxygen species generation, granule exocytosis with release of proteases, neutrophil extracellular trap (NET) formation, and release of cytokines. The current study focuses on PMN activation in response to SARS-CoV-2 infection, specifically, the association between NETs and lung disease. This is a prospective cohort study at an academic medical center with patients enrolled within 4 days of admission at 3 tertiary hospitals: Clements University Hospital, Parkland Memorial Hospital, and Children’s Health in Dallas, TX. Patients were categorized as having minimal or moderate to severe lung disease based on peak respiratory support. Healthy donor controls matched for age, sex, race, and ethnicity were also enrolled. Neutrophils from COVID-19 patients displayed greater IL-8 expression, elastase release, and NET formation as compared with neutrophils from healthy donors. Importantly, neutrophils from COVID-19 patients had enhanced NET formation in the absence of any additional stimulus, not seen in PMN from healthy donors. Moreover, PMA-elicited NET formation by circulating PMN correlated with severity of lung disease. We speculate that neutrophil immuno-phenotyping can be used to predict lung disease severity in COVID-19 patients.
Appendix
Available only for authorised users
Literature
5.
go back to reference Lam, C.W., M.H. Chan, and C.K. Wong. 2004. Severe acute respiratory syndrome: Clinical and laboratory manifestations. Clinical Biochemist Reviews 25 (2): 121–132.PubMedPubMedCentral Lam, C.W., M.H. Chan, and C.K. Wong. 2004. Severe acute respiratory syndrome: Clinical and laboratory manifestations. Clinical Biochemist Reviews 25 (2): 121–132.PubMedPubMedCentral
32.
go back to reference WHO. 2020. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. WHO. 2020. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis.
45.
go back to reference Wang, P., et al. 1994. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. The Journal of Immunology 153 (2): 811–816.PubMed Wang, P., et al. 1994. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. The Journal of Immunology 153 (2): 811–816.PubMed
47.
go back to reference Sahebnasagh, A., et al. 2020. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. Journal of Clinical Pharmacy and Therapeutics 45 (6): 1515–1519. https://doi.org/10.1111/jcpt.13251.CrossRefPubMed Sahebnasagh, A., et al. 2020. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. Journal of Clinical Pharmacy and Therapeutics 45 (6): 1515–1519. https://​doi.​org/​10.​1111/​jcpt.​13251.CrossRefPubMed
Metadata
Title
Neutrophil Extracellular Trap Formation Potential Correlates with Lung Disease Severity in COVID-19 Patients
Authors
Nedha Kinnare
Jessica S Hook
Parth A Patel
Nancy L Monson
Jessica G Moreland
Publication date
01-04-2022
Publisher
Springer US
Published in
Inflammation / Issue 2/2022
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-021-01585-x

Other articles of this Issue 2/2022

Inflammation 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.